Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience

Ebrahim S. Delpassand, Amin Samarghandi, Sara Zamanian, Edward M. Wolin, Mohammadali Hamiditabar, Gregory D. Espenan, Jack L. Erion, Thomas M. O'Dorisio, Larry K. Kvols, Jaime Simon, Robert Wolfangel, Arthur Camp, Eric P. Krenning, Alireza Mojtahedi

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Fingerprint Dive into the research topics of 'Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: The first US phase 2 experience'. Together they form a unique fingerprint.

Medicine & Life Sciences